Narcolepsy Articles & Analysis
5 news found
Tris’ CNS portfolio includes FDA-approved products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and a pipeline of treatments for pain, addiction, spasticity and narcolepsy. For more information, please visit www.trispharma.com and ...
Pitolisant has an orphan designation in the EU and the US for the treatment of narcolepsy. The drug pitolisant is distributed under the trade name Wakix® in the European Union and the United States for the treatment of narcolepsy in adult patients with and without cataplexy. About Narcolepsy Narcolepsy is a rare, ...
Among these, three assets are licensed from global partners and are now in the pre-NDA stage in China (WAKIX® indicated for narcolepsy, Alkindi® indicated for pediatric CAH, and Efmody® indicated for adult CAH); another three assets are in-house developed assets targeting LSD related diseases and are currently in IND-enabling stage in China. ...
RareStone's lead product candidate,Wakix®(pitolisant),is an investigational oral drug in development for the treatment of narcolepsy and obstructive sleep apnea in China. RareStone also recently announced two strategic partnerships that will allow the company exclusive rights to develop,register,and commercialize Alkindi®for pediatric congenital adrenal hyperplasia (CAH) ...
Citrine's lead product candidate, Wakix® (pitolisant), is an investigational oral drug in development for the treatment of narcolepsy and obstructive sleep apnea in China. Citrine has initiated an Investigational New Drug (IND) submission for pitolisant in the treatment of narcolepsy and expects to complete the IND submission in the first quarter of 2021. ...